Morules in endometrioid proliferations of the uterus and ovary consistently express the intestinal transcription factor CDX2

Histopathology

Volumn 53, Issue 2, 2008, Pages 156-165

  Houghton, O ^a   Connolly, L E ^a   McCluggage, W G ^a  

^a ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

CDX2; Endometrium; Immunohistochemistry; Morules; Ovary

Indexed keywords

BETA CATENIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYTOKERATIN; ESTROGEN RECEPTOR; PROTEIN P63; TRANSCRIPTION FACTOR CDX2;

ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; ELECTRON MICROSCOPY; ENDOMETRIOID CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; OVARY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL; UTERUS;

BETA CATENIN; CARCINOMA, ENDOMETRIOID; CELL NUCLEUS; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; INTESTINES; OVARIAN NEOPLASMS; OVARY; PROSPECTIVE STUDIES;

EID: 47749156446     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2008.03083.x     Document Type: Article

References (40)

1. Mazur MT, Kurman RJ. Endometrial hyperplasia, endometrial intraepithelial carcinoma, and epithelial cytoplasmic change. In Mazur MT, Kurman RJ eds. Diagnosis of endometrial biopsies and curetting. A practical approach. Berlin: Springer, 2005 178 207.
2. Zaino RJ, Kurman R, Herbold D et al. The significance of squamous differentiation in endometrial carcinoma: data from a gynecologic oncology study group. Cancer 1991 68 2293 2302.
3. Buckley CH. Normal endometrium and non-proliferative conditions of the endometrium. In Fox H, Wells M eds. Haines and Taylor obstetrical and gynaecological patholog, 5th edn. London: Churchill Livingstone, 2003 391 441.
4. Saegusa M, Okayasu I. Frequent nuclear beta-catenin accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation. J. Pathol. 2001 194 59 67.
5. Brachtel EF, Sánchez-Estevez C, Moreno-Bueno G et al. Distinct molecular alterations in complex endometrial hyperplasia (CEH) with and without immature squamous metaplasia (squamous morules). Am. J. Surg. Pathol. 2005 29 1322 1329.
6. Chiarelli S, Buriticá C, Litta P et al. An immunohistochemical study of morules in endometrioid lesions of the female genital tract: CD10 is a characteristic marker of morular metaplasia. Clin. Cancer Res. 2006 12 4251 4425.
7. Chinen K, Kamiyama K, Kinjo T et al. Morules in endometrial carcinoma and benign endometrial lesions differ from squamous differentiation tissue and are not infected with human papillomavirus. J. Clin. Pathol. 2004 57 918 926.
8. Dutra FR. Intraglandular morules of the endometrium. Am. J. Clin. Pathol. 1959 31 60 65.
9. Makishi S, Kinjo T, Sawada S et al. Morules and morule-like features associated with carcinomas in various organs: report with immunohistochemical and molecular studies. J. Clin. Pathol. 2006 59 95 100.
10. Li MK, Folpe AL. CDX-2, a new marker for adenocarcinomas of gastrointestinal origin. Adv. Anat. Pathol. 2004 11 101 105.
11. James R, Erler T, Kazenwadel J. Structure of the murine homeobox gene cdx-2. Expression in embryonic and adult intestinal epithelium. J. Biol. Chem. 1994 269 15229 15237.
12. Suh E, Chen L, Taylor J et al. A homeodomain protein related to caudal regulates intestine-specific gene transcription. Mol. Cell. Biol. 1994 14 7340 7351.
13. Escaffit F, Paré F, Gauthier R et al. Cdx2 modulates proliferation in normal human intestinal epithelial crypt cells. Biochem. Biophys. Res. Commun. 2006 342 66 72.
14. Saegusa M, Hashimura M, Kuwata T et al. A functional role of Cdx2 in beta-catenin signaling during transdifferentiation in endometrial carcinomas. Carcinogenesis 2007 28 1885 1892.
15. Werling RW, Yaziji H, Bacchi CE et al. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am. J. Surg. Pathol. 2003 27 303 310.
16. Groisman GM, Meir A, Sabo E. The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries. Int. J. Gynecol. Pathol. 2004 23 52 57.
17. De Lott LB, Morrison C, Suster S et al. CDX2 is a useful marker of intestinal type-differentiation: a tissue microarray-based study of 629 tumors from various sites. Arch. Pathol. Lab. Med. 2005 129 1100 1105.
18. Moskaluk CA, Zhang H, Powell SM et al. Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using microarrays. Mod. Pathol. 2003 16 913 919.
19. Kaimaktchiev V, Terracciano L, Tornillo L et al. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod. Pathol. 2004 17 1392 1399.
20. Tornillo L, Moch H, Diener PA et al. CDX-2 immunostaining in primary and secondary ovarian carcinomas. J. Clin. Pathol. 2004 37 641 643.
21. Raspollini MR, Amunni G, Villanucci A et al. Utility of CDX-2 in distinguishing between primary and secondary (intestinal) mucinous ovarian carcinoma: an immunohistochemical comparison of 43 cases. Appl. Immunohistochem. Mol. Morphol. 2004 12 127 131.
22. Logani S, Oliva E, Arnell PM et al. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma. Mod. Pathol. 2005 18 19 25.
23. Sah N, Yang XY, Tretiakova MS et al. Value of CDX2, villin, and alpha-methylacyl coenzyme A immunostaining in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Mod. Pathol. 2005 18 1217 1222.
24. Steininger H, Pfofe DA, Muller H et al. Expression of CDX2 and MUC2 in Barrett's mucosa. Pathol. Res. Pract. 2005 201 573 577.
25. McCluggage WG, Shah R, Connolly LE, McBride HA. Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2. Int. J. Gynecol. Pathol. 2008 27 92 100.
26. Morin PJ, Sparks AB, Korinek V et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997 275 1787 1790.
27. Polakis P. Wnt signaling and cancer. Genes Dev. 2000 14 1837 1851.
28. Ota S, Catasus L, Matias-Guiu X et al. Molecular pathology of atypical polypoid adenomyoma of the uterus. Hum. Pathol. 2003 34 784 788.
29. Sekine S, Shibata T, Matsuno Y et al. Beta-catenin mutations in pulmonary blastomas: association with morule formation. J. Pathol. 2003 200 214 221.
30. Xu B, Yoshimoto K, Miyauchi A et al. Cribriform-morular variant of papillary thyroid carcinoma: a pathological and molecular genetic study with evidence of frequent somatic mutations in exon 3 of the beta-catenin gene. J. Pathol. 2003 199 58 67.
31. Sekine S, Shibata T, Kokubu A et al. Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations. Am. J. Pathol. 2002 161 1997 2001.
32. Okamoto Y, Kashimara K, Daa T et al. Morule with biotin-containing intranuclear inclusions in thyroid carcinoma. Pathol. Int. 1995 45 573 579.
33. Hirokawa M, Kuma S, Miyauchi A et al. Morules in cribriform-morular variant of papillary thyroid carcinoma: immunohistochemical characteristics and distinction from squamous metaplasia. APMIS 2004 112 275 282.
34. Ueo T, Kashima K, Daa T et al. Immunohistochemical analysis of morules in colonic neoplasms: morules are morphologically and qualitatively different from squamous metaplasia. Pathobiology 2005 72 269 278.
35. Sasaki A, Yokoyama S, Arita T et al. Morules with biotin-containing optical clear nuclei in colonic tubular adenoma. Am. J. Surg. Pathol. 1999 23 336 341.
36. McCluggage WG, Oliva E, Herrington CS et al. CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma. Histopathology 2003 43 144 150.
37. Ordi J, Nogales FF, Palacin A et al. Mesonephric adenocarcinoma of the uterine corpus: CD10 expression as evidence of mesonephric differentiation. Am. J. Surg. Pathol. 2001 25 1540 1545.
38. O'Connell JT, Mutter GL, Cviko A et al. Identification of a basal/reserve cell immunophenotype in benign and neoplastic endometrium: a study with the p53 homologue p63. Gynecol. Oncol. 2001 80 30 36.
39. Wang TY, Chen BF, Yang YC et al. Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. Hum. Pathol. 2001 32 479 486.
40. McCluggage WG, Sumathi VP, Maxwell P. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. Histopathology 2001 39 82 83.